Form 4 for MDGL MADRIGAL PHARMACEUTICALS, INC.
Accepted 2023-11-22 00:00:00 ET · period of report 2023-11-20 · accession 0000950170-23-065902 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-11-22 | 2023-11-20 | MDGL | Huntsman Carole | Chief Commercial Off | A - Grant | $0.00 | +7,834 | 7,834 | New | $0 |
| D | 2023-11-22 | 2023-11-20 | MDGL | Huntsman Carole | Chief Commercial Off | A - Grant | $0.00 | +10.1K | 10.1K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-20 | A | A | 7,834 | $0.00 | 7,834 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-11-20 | A | A | 10,077 | $0.00 | 10,077 | D | $190.05 · — to 2033-11-20 | 10,077 Common Stock | (F2) The option vests as to 25% of the shares on the first anniversary of the date of grant (November 20, 2024) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. |